| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
|
Felip, Enriqueta
|
|
|
172 |
C |
p. 94-99
|
artikel
|
| 2 |
Barriers and facilitators to uptake of lung cancer screening: A mixed methods systematic review
|
Lin, Yu-an
|
|
|
172 |
C |
p. 9-18
|
artikel
|
| 3 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
|
Wang, Chunsheng
|
|
|
172 |
C |
p. 86-93
|
artikel
|
| 4 |
Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study
|
Lin, Miaozhen
|
|
|
172 |
C |
p. 29-34
|
artikel
|
| 5 |
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer
|
Sentana-Lledo, Daniel
|
|
|
172 |
C |
p. 124-126
|
artikel
|
| 6 |
Contents
|
|
|
|
172 |
C |
p. v-vi
|
artikel
|
| 7 |
Development and validation of nomograms based on clinical characteristics and CT reports for the preoperative prediction of precise lymph node dissection in lung cancer
|
Xiong, Lecai
|
|
|
172 |
C |
p. 35-42
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
172 |
C |
p. iii
|
artikel
|
| 9 |
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study
|
Addeo, Alfredo
|
|
|
172 |
C |
p. 154-159
|
artikel
|
| 10 |
Identification of necroptosis-related signature and tumor microenvironment infiltration characteristics in lung adenocarcinoma
|
Liu, Taisheng
|
|
|
172 |
C |
p. 75-85
|
artikel
|
| 11 |
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment
|
Akhave, Neal
|
|
|
172 |
C |
p. 19-28
|
artikel
|
| 12 |
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany
|
Griesinger, Frank
|
|
|
172 |
C |
p. 65-74
|
artikel
|
| 13 |
Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement
|
Navani, Neal
|
|
|
172 |
C |
p. 142-153
|
artikel
|
| 14 |
Organoids in lung cancer: A teenager with infinite growth potential
|
Xu, Yiming
|
|
|
172 |
C |
p. 100-107
|
artikel
|
| 15 |
Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer
|
Ma, Tianyu
|
|
|
172 |
C |
p. 43-52
|
artikel
|
| 16 |
Perioperative targeted therapy for oncogene-driven NSCLC
|
Liu, Si-Yang
|
|
|
172 |
C |
p. 160-169
|
artikel
|
| 17 |
Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients
|
Huang, Yihua
|
|
|
172 |
C |
p. 117-123
|
artikel
|
| 18 |
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer
|
Sagie, Shira
|
|
|
172 |
C |
p. 136-141
|
artikel
|
| 19 |
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)
|
Minegishi, Yuji
|
|
|
172 |
C |
p. 1-8
|
artikel
|
| 20 |
Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm
|
Stamatis, Georgios
|
|
|
172 |
C |
p. 108-116
|
artikel
|
| 21 |
The evolving role of liquid biopsy in lung cancer
|
Malapelle, Umberto
|
|
|
172 |
C |
p. 53-64
|
artikel
|
| 22 |
The impact of COVID-19 on thoracic surgical procedures in Japan: Analysis of data from the National Clinical Database
|
Sato, Yukio
|
|
|
172 |
C |
p. 127-135
|
artikel
|
Tijdschrift beschrijving